Pharmaceuticals, Biotechnology and Life Sciences
Boston-based Albireo Pharma, a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, has completed its public offering of…
AstraZeneca Friday said its Phase III KRONOS trial showed that PT010 improvement compared with dual combination therapies in six out…
AstraZeneca and its global biologics research and development arm, MedImmune, said on Friday that the Japanese Ministry of Health, Labour…
AstraZeneca and Merck have announced that the Japanese Ministry of Health, Labour and Welfare has approved Lynparza (olaparib) tablets (300mg…
The FDA has expanded the use of AstraZeneca’s Lynparza, the treatment for certain types of breast cancer patients, making it the…
The European Commission (EC) has approved AstraZeneca’s Fasenra as an add-on maintenance treatment in certain adult patients with severe eosinophilic…
Horizon Pharma has licensed the global rights to MEDI4945, a pre-clinical, genetically engineered uricase derivative combined with site-specific PEGylation, from…
The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for the use of AstraZeneca’s…
Faron Pharmaceuticals has appointed Dr. Juhana Heinonen as Chief Commercial Officer to join the company in January 2018.
The European Medicines Agency has accepted a variation to the Marketing Authorisation Application (MAAv) for Tagrisso (osimertinib) from Astrazeneca.